Molecular therapy for Pulmonary arterial hypertension: Lactolose (brand name: Cholac, Generlac, Consulose, Duphalac, others) inhibits the development of pulmonary arterial hypertension (PAH) via down-regulation of its target gene Notch3, 6/March/2019, 9.41 pm

Probiotic-based therapy for lowering cholesterol, and triglycerides levels: Lactobacillus rhamnosus GG (LGG) decreases the levels of HMGCR,  triglycerides, free cholesterol, and total cholesterol and prevents the progression of Non-alcoholic fatty liver disease (NAFLD), via up-regulation of its target gene, 5/March/2019, 6.41 pm
March 5, 2019
Anti-infective Therapy:  Troglitazone (brand name: Rezulin, Resulin, Romozin, Noscal), an anti-hyperglycemic drug, inhibits Hepatitis-B/C, Dengue, Zika, Ebola, HIV-1, Mtb, Malaria, CMV, Influenza H1NI1,  respiratory syncytial,  Sindbis, and SFV viruses by increasing the Levels of the Antiviral Proteins IFITM3, & Interferon-stimulated gene 15, 6/March/2018,  10.19 pm
March 6, 2019
Show all

What they say:  

A study from the University of California, La Jolla, California, USA shows that Notch3 signaling promotes the development of pulmonary arterial hypertension.” This study was published, in the 15 November  2009 issue of the journalNature Medicine[the number 1 journal in General Medicine with an I.F of 28.054],  by Prof. Thistlethwaite PA, Li X and others.


What we say: 

On the foundation of this interesting finding, Dr L Boominathan PhD, Director-cum-chief Scientist of GBMD, reports that:  Molecular therapy for Pulmonary arterial hypertension: Lactolose (brand name: Cholac, Generlac, Consulose, Duphalac, others) inhibits the development of pulmonary arterial hypertension (PAH) via down-regulation of its target gene Notch3


The significance of the study:  

This study suggests provide mechanistic insights into how the anti-hyperglycemic drug Pioglitazone may attenuate pulmonary arterial hypertension.

Lactoloseby increasing the expression of its target gene, it may decrease the expression of Notch3 and its target gene Hes-5 (Fig.1). Thereby, it may inhibit and promote, respectively, proliferation and differentiation of smooth muscle cells. And, thereby, prevent pulmonary hypertension (Figure 1).  Thus, Lactolose  or its analogs, either alone or in combination with other drugs,”may be used to treat pulmonary arterial hypertension (Fig. 2). 

Figure 1. Mechanistic insights into how Lactolose may function as an anti-pulmonary arterial hypertensive agent.  Lactolose may promote insulin sensitivity and protect against myocardial infarction, via up-regulation of reprogramming protein Lin-28

Figure 2. Lactolose may inhibit pulmonary arterial hypertension through down-regulation of Notch-3 and its target gene Hes5


Details of the research findings: 

Idea Proposed/Formulated byDr L Boominathan Ph.D.

Undisclosed mechanistic information: How does Lactolose decrease the expression of Notch3 and its target gene?

Amount: $500#

Terms & Conditions apply http://genomediscovery.org/registration/terms-and-conditions/

For purchase and payment details, you may reach us at info@genomediscovery.org

# Research cooperation


References: 

Web: http://genomediscovery.org or http://newbioideas.com/

CitationBoominathan, L., Molecular therapy for Pulmonary arterial hypertension: Lactolose (brand name: Cholac, Generlac, Consulose, Duphalac, others) inhibits the development of pulmonary arterial hypertension (PAH) via down-regulation of its target gene Notch3, 6/March/2019, 9.41 pm,  Genome-2-BioMedicine Discovery center (GBMD), http://genomediscovery.org

Courtesy: When you cite us, drop us a line at info@genomediscovery.org

Comments are closed.